From the Editor-in-Chief's Desk: Advances in Patient-Centered Treatment for Attention-Deficit/Hyperactivity Disorder

Childress AC , Marraffino A , Cutler AJ , et al. Safety and tolerability of serdexmethylphenidate/dexmethylphenidate capsules in children with attention-deficit/hyperactivity disorder: A 12-month, open-label safety study. J Child Adolesc Psychopharmacol, 2023; 33(2):51–58; doi: 10.1089/cap.2022.0076

Cortese S , Coghill D , Mattingly GW , et al. AACAP endorses the inclusion of methylphenidate in the WHO model lists of essential medicines. J Am Acad Child Adolesc Psychiatry, 2024; 28:S0890-8567(24)00076-5; doi: 10.1016/j.jaac.2024.02.008 Online ahead of print.

Cortese S , McGinn K , Højlund M , et al. The future of child and adolescent clinical psychopharmacology: A systematic review of phase 2, 3, or 4 randomized controlled trials of pharmacologic agents without regulatory approval or for unapproved indications. Neurosci Biobehav Rev, 2023; 149:105149.doi:10.1016/j.neubiorev.2023.105149

Cutler AJ , Suzuki K , Starling B , et al. d-Amphetamine transdermal system in treatment of children and adolescents with attention-deficit/hyperactivity disorder: Secondary endpoint results and post hoc effect size analyses from a pivotal trial. J Child Adolesc Psychopharmacol, 2023; 33(5):176–182; doi: 10.1089/cap.2023.0005.

Hill DM , Sibley MH , Stein MA , et al. Longitudinal patterns of community-based treatment utilization among ethnically and racially diverse adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol, 2024; 34(3):119–126; doi: 10.1089/cap.2023.0042

Hutt Vater C , Biederman J , DiSalvo M , et al. Growth trajectories in stimulant treated children and adolescents: A qualitative review of the literature from comprehensive datasets and registries. J Child Adolesc Psychopharmacol, 2023; 33(9): 344–355; doi: 10.1089/cap.2023.0054

Ruiz E , Beatty A , Weyandt L . An investigation of diversity in childhood and adolescent antidepressant studies: A systematic review. J Child Adolesc Psychopharmacol, 2023; 33(5):164–175; doi: 10.1089/cap.2022.0090

Søndergaard NR , Nørøxe KB , Carlsen AH , et al. Switch to lisdexamfetamine in the treatment of attention-deficit disorder at a psychiatric outpatient clinic for school-aged children: A Danish cohort study. J Child Adolesc Psychopharmacol, 2024; 34(3):137–147; doi: 10.1089/cap.2023.0077

Zhu D , Zito JM , Gardner JF , et al. Stimulant patterns, alone or with other psychotropic classes, in Medicaid-insured youth continuously enrolled for 3–8 years. J Child Adolesc Psychopharmacol, 2024; 34(3):127–136; doi: 10.1089/cap.2023.0028